Novel medical approaches and personalized medicine seek to use genetic information to 'individualize' and improve diagnosis, prevention, and therapy. The personalized management of cardiovascular disease involves a large spectrum of potential applications, from diagnostics of monogenic disorders, to prevention and management strategies based on modifier genes, to pharmacogenetics, in which individual genetic information is used to optimize the pharmacological treatments.
INTRODUCTION
The International Human Genome Project was completed in 2003 after 13 years of extensive work by a network of laboratories and an approximately $3 billion investment. The 3 billion base pairs of the human genome became publicly available shortly after sequencing. This event and the extraordinary rapid change in technology have changed the way we perceive and practice medicine. Today, with novel sequencing technologies like massively parallel sequencing or next-generation sequencing (NGS), the cost of sequencing a human genome is less than $5000 and it can be completed in about a week. Furthermore, it is possible to sequence only the coding region of the genome, the exome, for less than $1000. It is expected that continued improvements of technology and bioinformatics analysis will further reduce the cost of whole-genome sequencing below $1000 (The Road to the $1000 Genome -A Roundup of Sequencing Technology Developments, http://www.genome. gov). Meanwhile, the '1000 Genomes Project' has currently sequenced the genomes of 2500 people of various ethnic origins and represents one of a growing number of sequenced human cohorts that provide data on the genetic variation in populations [1 & ]. The advances in genomics and high-throughput technologies are projected to profoundly impact cardiovascular medicine [2] . Out of 3 billion base pairs in the human genome, there are likely over 10 million common genetic variations that occur naturally, meaning that even two closely related individuals will possess thousands of genetic differences. A mutation rate of 2 Â 10 À8 per base pair in any given generation can thus lead to the accumulation of approximately 60 new mutations every generation [3 && ]. Within a genome, there are common variants, termed 'polymorphisms', that typically have no clinical consequences. However, some genetic variations in genes are functionally significant and account for differences in susceptibility or severity of diseases, or responses to drugs (pharmacogenetics). Drug response variation can be observed in large population studies and even within families. Genes that can aid in pharmacogenetic differences in the individual's response to disease or therapy are called modifier genes. Clinicians historically have included behavioral and environmental factors in personalized care, but it is only recently that genetic information has had the opportunity to be used in medicine as well [4 && ].
PHARMACOGENETICS
It has been estimated that more than 100 000 deaths in the United States occur each year because of adverse drug reactions, and pharmacogenetic differences in drug response may be one factor that contributes to these deaths [5] . Genes associated with variation in drug response have been identified using three major approaches. The first is the candidate-gene approach based on the identification of 'candidate variants' in well-defined pharmacokinetic pathways. The second and most recent approach is based on the genome-wide association studies (GWAS). Through December 2013, the Catalog of Genome-wide Association Studies of the National Human Genome Research Institute listed approximately 2050 published GWAS with significant findings (P < 5 Â 10 À8 ) in 17 trait categories (www.genome.gov/gwastudies). In GWAS, the approach is based on wholegenome screening of hundreds of thousands of single-nucleotide polymorphisms (SNPs), rather than by candidate genes. Once an association is discovered between a polymorphism and the disease, the modifier gene in proximity to the SNP is identified. The approach, thanks to the technological advances in high-throughput sequencing methods and bioinformatic approaches, relies on the screening of large populations of patients and controls, and has already been successfully utilized in cardiovascular medicine in complex common disorders such as hypertension and coronary artery disease [3 && ,6 && ]. The third tool to search for variants in the protein-coding regions of the genome, known as whole-exome sequencing (WES), analyzes the region of the genome most likely to contain pathogenic mutations and has been recently used in pharmacogenetics of drug metabolism [7 && ].
PHARMACOGENETICS OF HEART FAILURE
Heart failure is one of the most serious and expensive conditions in healthcare worldwide because of its high prevalence (1-1.5% of adult population) and high morbidity (frequent hospitalization). In the United States, heart failure affects approximately 4 million people and causes about 200 000 deaths per year, with a generally rapid course with a mean survival of only 1.7 years for men and 3.2 for women after diagnosis [8] . In Europe, data are substantially similar, which suggests that, in spite of the improvement of heart failure therapy, disease progression has not changed and heart failure still remains one of the most important health issues in the world.
Heart failure is a syndrome characterized by primary pathophysiological processes, which interact with a wide number of complex secondary interrelated pathophysiological mechanisms. Heart failure is mediated by rare mutations in single Mendelian genes, in addition to the common genetic polymorphisms in modifier genes that can modify the natural history of the cardiac disease. Known heart failure modifiers include genes of the reninangiotensin-aldosterone (RAAS) and adrenergic systems [9, 10] . Furthermore, genetic polymorphisms can modify the response to therapy [9] [10] [11] by changing gene-gene interactions, such as b 1 and a 2 adrenergic receptors [12] .
Several studies have provided evidence of the existence of modifier genes in heart failure that can modulate the severity and progression of the disease independently from the primary cause of the disease or monogenic disorder. Lee et al. [13] in the Framingham Offspring Study have shown that the risk of heart failure is significantly increased in the offspring of patients with heart failure
KEY POINTS
Polymorphisms in many genes lead to variability in drug effectiveness and safety, as demonstrated by the studies involving b-blockers, warfarin, clopidogrel, and others.
As the cost of DNA sequencing drops, GWAS and WES will lead to the identification of new gene-drug interactions with clinical relevance.
Additional studies are needed to elucidate the mechanisms of gene-drug interactions leading to differences in patients' responses.
Clinicians' understanding of the pharmacogenetic interactions is key to helping patients get the best treatment with cardiovascular drugs that are produced today.
compared with controls. Furthermore, in monogenic cardiomyopathies, there is frequently high intrafamilial variability of the phenotype, consistent with the presence of genetic variation contributing to phenotypic variation [9] . Finally, studies on the effect of candidate-gene polymorphisms have shown that genetic variations can influence the heart failure phenotype and the mutant protein function [9, 10] . Examples of modifier variants include the DD genotype of the angiotensin-converting enzyme (ACE), in which patients homozygous for the deletion (D) have increased circulating and myocardial ACE levels. These patients are at risk of early heart remodeling after myocardial infarction, as well as risk of severe systolic dysfunction in dilated cardiomyopathy (DCM) and ischemic cardiomyopathy [9, 10] . Other polymorphisms that can modify the natural history of DCM are the AT 1 receptor, b 1 -adrenergic and b 2 -adrenergic receptors, and the a 2C -adrenergic receptor [9] [10] [11] [12] [13] .
A more comprehensive approach to identifying modifier genes in heart failure is expected to come from GWAS, such as in the Framingham Heart Study (FHS). Two recent studies have reported a large meta-analysis of the risk of heart failure and mortality in the Cohorts for Heart and Aging Research in Genetics Epidemiology (CHARGE) Consortium [14, 15] . The study population included 20 926 European ancestry participants and 2895 African ancestry participants previously enrolled in four smaller studies from the USA and the Netherlands: the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study (CHS), the FHS, and the Rotterdam Study. The first analysis of Smith et al. [14] on the risk of developing heart failure identified two loci, USP3 in patients of European ancestry and LRIG3 in patients of African ancestry, with genome-wide significance (P < 10 À8 ). The USP3 gene encodes an ubiquitinspecific protease: ubiquitin is a highly conserved protein involved in important cellular processes, such as protein degradation, cell-cycle regulation and stress response, and is activated in cardiomyopathies and pathogenic cardiac hypertrophy. The LRIG3 gene encodes a member of the LRIG family (leucine-rich repeat and immunoglobulin-like domain proteins), integral membrane proteins widely expressed and involved in tissue development [14] . In the second study, Morrison et al. [15] analyzed the subgroup of CHARGE participants who developed heart failure (2526 individuals of European ancestry and 466 of African ancestry) and estimated the risk of mortality. One locus was identified in the European subgroup, with genomewide significance (P < 10 À7 ), in the CKLF-like MARVEL transmembrane domain containing 7 (CMTM7) gene, one of the chemokine-like factor genes clustered on chromosome 3p22. Although its function is still unknown, CMTM7 appears to be expressed in leukocytes and in the heart, may be upregulated in heart failure, and may act as a chemoattractant to guide migration of cells in the heart [15] . For this information to lead to a clinical impact, the functional significance of the modifier genes identified needs to be further elucidated and the studies replicated in independent prospective heart failure cohorts.
In heart failure, pharmacogenetics has a promising role: indeed, in spite of the improvement in the natural history of heart failure, thanks to the therapeutic advancement in the last 20 years and the development of practice guidelines, large clinical trials such as Beta Blocker Evaluation Survival Trial (BEST) and African-American Heart Failure Trial (AHeFT) have suggested that some patients have a different response to treatment (responders versus nonresponders) because of the underlying genetic differences [16] . The most important genetic variations associated with these different pharmacological responses are listed in Table 1. In the BEST trial, the initial evaluation of bucindolol, a b-blocker and sympatholytic agent, on patients with heart failure in class 3 and 4 was disappointing and did not reach statistical significance. However, when the investigators analyzed the response to treatment based on the b 1 adrenergic receptor genotype encoded by ADBR1, they found a strong association with the amino acid at position 389 [17] . Wildtype Arg389 homozygotes responded significantly better than Arg389Gly polymorphism carriers to the drug treatment, with a 38% reduction in mortality. The wildtype Arg389 response was even better than that previously reported for carvedilol [10, 17] . The different behavior of the two allelic variants is explained by the fact that the wildtype allele is more responsive to the agonist stimulation (isoproterenol) than the Arg389Gly variant allele [10, 17] , a response confirmed by other studies involving different b-blockers including metoprolol and carvedilol [16] (Fig. 1) .
More recently, the BEST investigators reported the results of a substudy on the pharmacogenetic effect of the a 2C -adrenergic receptor, whose role is to inhibit norepinephrine release in the prejunctional adrenergic nerve terminals. The polymorphism a 2C Del322-325 had previously been associated with a worse prognosis in heart failure, with evidence for a synergistic effect with the b 1 Arg389 allele in black patients [18] . In another study, Bristow et al. [19] demonstrated that the norepinephrine-lowering and clinical therapeutic responses to bucindolol were strongly influenced by the a 2C receptor genotype. The a 2C Del322-325 carriers had an excessive sympatholytic effect and no evidence of any therapeutic benefit from bucindolol, whereas wildtype a 2C carriers had a 30% reduction in mortality.
Many polymorphisms, such as the b 1 extracellular adrenergic receptors with polymorphisms Ser49Gly and Arg389Gly, can aid in the modification of heart failure. Also, polymorphisms of the b 2 adrenergic receptor can modify heart failure (Table 1 ). In the RAAS system, patients with the ACE DD genotype had a worse prognosis, but at the same time were the best responders to b-blocker therapy compared with the other genotypes [9] . It is interesting to note that the evidence of a genetically driven response to therapy in heart failure dates back to the AHeFT. In this trial, the investigators found that African-American patients had a much better response to the therapy with hydralazine and isosorbide dinitrate compared with Caucasian patients. Indeed, this is the first Federal Drug Administration (FDA)-approved therapy for heart failure based on the racial differences and consequently on genetic background [20] . Data of the Genetic Risk Assessment of Heart Failure in AHeFT (GRAHF) substudy suggests that at least one of the genetic causes lies in the -344C/T polymorphism located in the promoter of the aldosterone synthase gene, which is associated with a worse prognosis but a better response to the hydralazine and isosorbide dinitrate therapy in carriers: the same polymorphisms had previously been associated with higher enzymatic activity, hypertension, and myocardial remodeling [16] . The studies on b 1 -a 2C receptors indicate the existence of complex gene-gene interactions in the genetic determinants of heart failure. In particular, the gene-gene interaction and the functional effect in the case of the adrenergic receptors are of particular interest. The b 1 Arg389 receptor is more responsive to the adrenergic stimulation: patients homozygous for the Arg389 allele carrying also the a 2C Del322-325 receptor characterized by decreased uptake of norepinephrine seem to have an enhanced adrenergic response, but a worse prognosis. However, they have the greatest improvement in ejection fraction with b-blocker therapy [19] .
Finally, we have studied the association of polymorphisms of the endothelin system with heart failure in the BEST cohort [11] . Two genetic variations (IVS-4 G/A and Lys198Asn) on a common haplotype in the endothelin-1 gene were associated with differential response to bucindolol in terms of a combined endpoint of heart failure hospitalization and cause of death (Fig. 2) . The effect of the endothelin-1 haplotype was only evident in the treatment group, supporting a pharmacogenetic interaction between bucindolol and the haplotype. Ultimately, these types of data collecting could be used to tailor b-blocker therapy for individuals based on their underlying endothelin-1 haplotype [11] .
OTHER AREAS OF PHARMACOGENETIC INVESTIGATIONS IN HEART-FAILURE-ASSOCIATED THERAPIES
Arrhythmias are frequent comorbidities in heart failure and have recently been associated with pharmacogenetic markers in the context of antiarrhythmic drugs. First of all, several antiarrhythmic drugs can induce arrhythmias by inducing a prolongation of the QT interval (drug-induced long QT syndrome), such as sotalol, dofetilide, and quinidine. Subclinical long QT syndrome (LQT) appears to be the cause of a large proportion of these cases and seems to be associated with genetic variations of LQT genes [2] . There is a critical need for a mechanism to identify patients at risk for potentially life-threatening drug-induced arrhythmias. Pharmacogenetics of the G-protein b3 subunit (GNB3) c825t polymorphism may allow a better identification of patients who will benefit from implantable cardiac defibrillators and biventricular pacing in heart failure [21] . A major field of interest has been the study of pharmacogenomics of warfarin therapy. The genes that appear to play the most important role are CYP2C9 and VKORC1 (40-50% drug variability) [22] . The gene VKORC1 has been found to be the main predictor as well as variants in its promoter region [23] . Furthermore, CYP2C9Ã2 and CYP2C9Ã3 are associated with lower warfarin dose requirements and increased risk of bleeding, which can result in a longer hospital stay [4 && ]. In spite of the several studies on warfarin pharmacogenomics, the clinical utility of pharmacogenetic testing for anticoagulation control is still not completely well established. Some studies have been conducted, but suffer from small sample sizes [3 && ]. A pharmacogenomic algorithm has been developed, giving an estimate of the dosage requirement for patients taking warfarin [24] depending on the polymorphisms in the warfarin candidate genes (CYP2C9 and VKORC1; http://www.warfarindosing.org) [22] . The FDA has created a black box warning on the efficacy of this drug based on genetic testing conclusions [24,25 && ]. However, the real clinical utility of pharmacogenetic screening for anticoagulant therapy is still unclear, ] have provided mixed and apparently contradictory results.
Another field of interest in cardiovascular pharmacogenomics is the dose response in antiplatelet agents, especially the dual antiplatelet therapy of aspirin with a P2Y 12 inhibitor drug. Clopidogrel shows a wide range of dose responses, and variability has been associated with loss-of-function mutations in CYP2C19Ã2 and CYP2C19Ã3, which cause a reduced conversion of clopidogrel (prodrug) into its active metabolite [2, 28] . Carriers have an increased risk of cardiovascular events and in-stent restenosis. The FDA approved a written warning alert to the pharmacogenetic findings and the availability of alternative therapies for CYP2C19Ã2 carriers. Prasugrel utilizes CPY3A4 and CYP2B6 for the drug activation, and is therefore recommended when the CYP2C19 gene has a loss-of-function allele. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON TIMI 38) trial found that CYP2C19 polymorphisms can cause major cardiovascular events, but dual antiplatelet therapy helps to relieve that issue [3 && ]. Finally, pharmacogenetic associations with response to exercise have been examined by Wagoner et al. [29] , who found that b(2)-adrenergic receptor polymorphisms may determine the exercise capacity in patients with heart failure.
CONCLUSION
A new era of personalized medicine is poised to enter clinical practice, and it is fueled by the decrease in the cost of DNA sequencing. Ideally, tailoring therapy based on pharmacogenomic tests would save lives and improve patient care. Advances in technologies continue to facilitate this transition from the research to the clinical setting, reshaping the clinical diagnostic paradigms and challenging the healthcare team to consider how new genomic information may be leveraged to influence management decisions and to realize the promise of personalized medical care. GWAS studies and other large population studies along with enhanced mechanisms to analyze the genetic data are critical for the progression of pharmacogenomics. However, many challenges still remain in applying pharmacogenetics to the clinical practice in heart failure management, and the clinical utility of pharmacogenetic testing in cardiovascular patients still remains elusive [30 & ]. Physicians and cardiologists will need to understand, communicate, and manage this new genomic information to provide the patient with appropriate education and management recommendations.
